Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026 [Yahoo! Finance]
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026
Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit
Vaxcyte Funding And Late-Stage Trials Put Valuation In Focus [Yahoo! Finance]